Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ECYT
Delisted

Endocyte Fund Price (Quote)

$23.99
+0 (+0%)
At Close: Jan 18, 2019

Range Low Price High Price Comment
30 days $23.97 $24.00 Friday, 18th Jan 2019 ECYT stock ended at $23.99. During the day the stock fluctuated 0% from a day low at $23.99 to a day high of $23.99.
90 days $23.37 $24.00
52 weeks $2.81 $24.00

Historical Endocyte prices

Date Open High Low Close Volume
Dec 12, 2018 $23.85 $23.89 $23.83 $23.85 1 407 053
Dec 11, 2018 $23.85 $23.89 $23.84 $23.84 1 377 779
Dec 10, 2018 $23.83 $23.87 $23.80 $23.85 2 058 204
Dec 07, 2018 $23.83 $23.86 $23.83 $23.83 1 406 694
Dec 06, 2018 $23.83 $23.86 $23.79 $23.84 2 183 036
Dec 04, 2018 $23.85 $23.94 $23.85 $23.85 1 746 927
Dec 03, 2018 $23.90 $23.91 $23.80 $23.88 4 914 272
Nov 30, 2018 $23.47 $23.70 $23.45 $23.63 3 199 046
Nov 29, 2018 $23.50 $23.60 $23.42 $23.42 3 617 784
Nov 28, 2018 $23.59 $23.63 $23.39 $23.49 2 824 744
Nov 27, 2018 $23.59 $23.64 $23.57 $23.59 1 472 467
Nov 26, 2018 $23.62 $23.67 $23.58 $23.60 2 031 472
Nov 23, 2018 $23.59 $23.64 $23.58 $23.60 703 674
Nov 21, 2018 $23.60 $23.64 $23.56 $23.60 1 251 429
Nov 20, 2018 $23.60 $23.63 $23.55 $23.57 1 657 525
Nov 19, 2018 $23.63 $23.66 $23.56 $23.62 1 635 643
Nov 16, 2018 $23.62 $23.69 $23.61 $23.67 1 274 089
Nov 15, 2018 $23.56 $23.61 $23.50 $23.61 2 182 876
Nov 14, 2018 $23.66 $23.69 $23.53 $23.53 1 796 879
Nov 13, 2018 $23.60 $23.76 $23.53 $23.58 1 998 151
Nov 12, 2018 $23.54 $23.65 $23.52 $23.55 1 335 231
Nov 09, 2018 $23.62 $23.66 $23.53 $23.56 1 584 959
Nov 08, 2018 $23.65 $23.70 $23.59 $23.66 1 269 365
Nov 07, 2018 $23.70 $23.77 $23.57 $23.66 1 459 504
Nov 06, 2018 $23.64 $23.85 $23.57 $23.85 1 426 596
Click to get the best stock tips daily for free!

About Endocyte

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of ad... ECYT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT